DC
RVPH

Davenport & Co’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Davenport & Co’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-500
Closed -$49K – 1045
2021
Q2 		$49K Sell
500
-250
-33% -$25.2K ﹤0.01% 937
2021
Q1 		$86K Buy
+750
New +$125K ﹤0.01% 780

Other funds holding RVPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ECM
EMC Capital Management Houston, Texas $253M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Davenport & Co's RVPH Position: Q3 2021 in Review

Davenport & Co sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q3 2021, closing a stake of 500 shares — an estimated $49K sold.

Davenport & Co first reported a position in RVPH in Q1 2021 and held it in 2 quarters. The position peaked at $86K in Q1 2021. 12 funds tracked by Wall St. Rank hold RVPH as of Q3 2021.

  • Davenport & Co reported no remaining REVIVA PHARMA HLDGS INC position as of Q3 2021 after selling out during the quarter.
  • Davenport & Co sold 500 REVIVA PHARMA HLDGS INC shares in Q3 2021, an estimated $49K.
  • Davenport & Co first reported a position in REVIVA PHARMA HLDGS INC in Q1 2021 and held it in 2 quarters.
  • Davenport & Co's REVIVA PHARMA HLDGS INC position peaked at $86K in Q1 2021.
  • 12 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q3 2021.

Based on Davenport & Co's 13F filing for Q3 2021, filed 14 Oct 2021.